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Abstract
Arteriovenous malformations (AVM) are vascular malformations composed 
of a network of abnormal vessels connecting directly between the artery and 
vein without an intervening capillary bed. Cerebral arteriovenous malforma-
tions have an incidence of 0.8–1.3 per 100.000 person years. Clinical symptoms 
include intracranial hemorrhage, seizure, headache, and focal neurological 
deficit. Annual mortality rate associated with hemorrhage is 1–5%, and 10–30% 
of survivors will have disability. Treatment options for cerebral AVMs include 
open surgery, embolization, and radiosurgery. Depending on the grade and 
angioarchitectural characteristics, a combination of these modalities can be 
used. Endovascular treatment can be performed for size and grade reduction, 
presurgical devascularization, size reduction before radiosurgery, targeted 
embolization, and as stand-alone treatment for cure. Targeted embolization 
can address intranidal or flow-related aneurysms and high flow arteriovenous 
shunts. Complications of the endovascular treatment include hemorrhage 
related to vessel perforation or normal pressure breakthrough phenomenon, 
ischemia, microcatheter retention, and other general complications associated 
with angiographic procedures. Mortality associated with endovascular treatment 
is less than 2% and permanent neurological deficit can be seen up to 2–8.9% 
of cases. New endovascular techniques include balloon-assisted embolization, 
transvenous embolization, and double microcatheter techniques like pressure 
cooker technique.
Keywords: cerebral arteriovenous malformation, intracranial hemorrhage, 
endovascular, embolization
1. Introduction
Arteriovenous malformations (AVM) are vascular malformations composed 
of a network of abnormal vessels connecting directly between the artery and vein 
without an intervening capillary bed. AVMs are thought to be congenital lesions 
originated from persistence of primitive arteriovenous connections [1].
1.1 Epidemiology
According to epidemiological studies, including Netherland Antilles [2], 
Olmsted county Minnesota [3], and New York islands [4], incidence of cerebral 
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arteriovenous malformations is between 0.8 and 1.3 per 100.000 person years. In 
addition to sporadic cases, brain AVMs can be associated with syndromes including 
hereditary hemorrhagic telangiectasia, Wyburn-Mason syndrome, and Sturge-
Weber syndrome [5, 6].
1.2 Clinical presentation
Symptomatic brain AVMs may present with intracranial hemorrhage (50%), 
seizure (33%), headache (16%), or focal neurologic deficit (6%) [7]. Annual risk 
of bleeding of due to brain AVMs is approximately 2–4%. Risk factors increasing 
the odds of bleeding include prior history of intracranial bleeding due to AVM, 
deep location, exclusive deep venous drainage and single draining vein, intrani-
dal aneurysm, and high intranidal pressure [7–9]. When there are three factors, 
risk may increase up to 34%. In patients presenting with hemorrhage, rebleeding 
risk in the first year is approximately 32% that decrease to 11% in subsequent 
years [10]. Annual mortality rate is approximately 1.5% and 10–30% of survivors 
have long-term disability. Neurological disability is more common in ruptured 
AVMs compared to aneurysm rupture due to higher likelihood of a lobar hema-
toma [11]. Although there is conflictive data, smaller AVMs have a higher ten-
dency to present with hemorrhage. Spetzler et al. [12] found that 82% of smaller 
AVMs (<3 cm) present with hemorrhage compared to 21% of hemorrhage seen 
in larger AVMs (>6 cm). Ondra et al. [13] published a series of 160 symptomatic 
untreated AVM cases and found that 23% of the patients died during a mean 
follow-up of 23.7 years.
1.3 Therapeutic strategies
AVM treatment includes medical management, surgical, endovascular, and 
radiosurgical modalities. ARUBA, largest multicenter randomized trial to date, 
showed that medical management alone is superior to interventional therapy for 
the prevention of death and stroke in patients with unruptured AVMs [14, 15]. 
However, the follow-up period in this study was only 33 months, and 5-year 
follow-up results that will prove whether these results are persistent are yet to 
be published. Nevertheless, ruptured AVMs, unruptured AVMs with significant 
risk factors, and some symptomatic AVMs in young patients must be treated. 
These treatment modalities can be used as stand-alone treatment for cure, or a 
combination of different techniques can be used to increase the efficiency and 
minimize the risks associated with treatment. Although there is still no consen-
sus on the ideal treatment, every case is evaluated specifically for its rupture 
risk and risks associated with its treatment. The most common grading system 
used to stratify the risks of surgical treatment of AVMs is the Spetzler-Martin 
system [16]. This system classifies the AVMs according to size, location, and 
venous drainage. Larger lesions, AVMs with deep venous drainage, and lesions in 
eloquent locations have higher surgical risk. Eloquent locations include senso-
rimotor cortex, visual cortex, thalamus, internal capsule, brainstem, cerebellar 
peduncles, and deep cerebellar nuclei. Deep venous drainage sites are straight 
sinus, internal cerebral veins, basal veins of Rosenthal, and precentral cerebellar 
veins. Spetzler and Ponce proposed a modified version of the grading system in 
2011 [17].
AVMs larger than 3 cm in a non-eloquent and superficial location can be safely 
treated with embolization followed by surgery. AVMs larger than 3 cm with a deep 
or eloquent location can be embolized and then radiosurgery can be used for the 
ultimate cure. Smaller lesions (<3 cm) can be safely treated with surgery alone or 
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radiosurgery can be used as stand-alone treatment in case of eloquent or deep loca-
tion. For ruptured small deeply located surgically inaccessible AVMs, embolization 
can be used as a stand-alone treatment for cure.
2. Endovascular treatment
The first report of embolization of an AVM was published by Luessenhop and 
Spence et al. in 1960 [18] who used methyl methacrylate pellets after a direct 
carotid puncture. Selective catheterization of the intracranial circulation with 
microcatheters was first described by Serbinenko et al. [19] and Kerber. Further 
evolution has occurred with the use of new liquid embolic agents like cyanoacry-
late by Drake et al. [20] and Debrun et al. [21]. After years of embolization with 
N-butyl cyanoacrylate, introduction of a new agent composed of ethylene vinyl 
alcohol polymer (Onyx, Medtronic, Irvine, CA, USA) has changed the practice 
of AVMs once more.
Endovascular treatment of cerebral AVMs can be used before open surgery, 
before radiosurgery, for cure as a stand-alone treatment, to target the weak 
angioarchitectural points, or for palliative purposes. The advantages of endo-
vascular treatment include minimally invasiveness, immediate angiographic 
evaluation during and after the treatment, and immediate occlusive effect. 
Angiography is the gold standard for the diagnosis and treatment planning for 
AVMs. Angiograms show the location, size, and number of arterial feeders and 
draining veins and locate weak points such as intranidal aneurysms, flow-related 
aneurysms, venous drainage stenosis, ectasia, or aneurysm of the draining 
veins. These angioarchitectural characteristics lead to decision on the treatment 
strategy for a specific AVM including surgical, endovascular, or radiosurgical 
techniques.
2.1 Embolization before surgical resection
Preoperative embolization reduces the blood loss during surgery and decreases 
surgery times. By decreasing the size of an AVM, the Spetzler-Martin grade and 
eventually surgical morbidity-mortality are decreased (Figure 1). Grade 1 and 
grade 2 AVMs, which are amenable to stand-alone surgery, may benefit from the 
embolization of the deeply located feeders. Grade 3 AVMs with deep and eloquent 
location can be treated with embolization preoperatively and surgical morbidity 
and mortality can be reduced significantly [22]. Presurgical embolization is the 
most beneficial for grade 3 AVMs.
2.2 Embolization before radiosurgery
Obliteration rates after radiosurgery decreases as the size of an arteriovenous 
malformation increases. Obliteration rate decreases from 80 to 50% when the 
size of the AVM increases from 2.5 to 3 cm [23]. The main aim of embolization 
before radiosurgery is to decrease the size of the lesion before radiosurgery [24] 
(Figure 2). AVMs larger than 3 cm can benefit significantly by embolization. A 
successful embolization obliterating the periphery of an AVM can help to decrease 
the required dose for obliteration and negative effects of the radiosurgery on the 
neighboring tissues [25]. If an AVM has intranidal aneurysms, these aneurysms can 
be embolized to decrease the bleeding risk during the latency period. Additionally, 
targeted embolization can be used to obliterate direct arteriovenous shunts in the 
arteriovenous malformations to increase the efficiency of the radiosurgery [26]. 
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Figure 1. 
(A–D) A ruptured choroidal AVM that caused intraventricular and subarachnoid hemorrhage in a 26-year-
old male. AVM is supplied by the right posterior cerebral artery (PCA), parietooccipital branch, medial and 
lateral posterior choroidal arteries, and right pericallosal artery from anterior cerebral artery (ACA).  
(E and F) Residual AVM supplied by en passage arterial feeders (arrows) from the posterior choroidal 
arteries and more than 90% size reduction after embolization. These en passage feeders were not amenable to 
embolization and patient went to surgery for AVM resection on the following day after embolization. Control 
angiogram after surgical resection does not demonstrate any evidence of a residual AVM (G and H).
Figure 2. 
(A and B) An unruptured left perirolandic AVM supplied by middle cerebral artery branches in a 46-year-
old female with headaches. (C) Superselective catheterization and angiogram during preradiosurgical 
embolization. Postembolization angiograms (D) show at least 90% size reduction with a small residual lesion 
in the Rolandic region. Stereotactic surgery is planned (E) following embolization due to eloquent location. 
Follow-up angiograms 2 years after radiosurgery (F and G) demonstrate complete obliteration of the AVM 
without any residual or recurrent lesion.
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There are conflictive reports in the literature regarding the efficiency of embolization 
before radiosurgery. Whereas some studies have recently mentioned decreased oblit-
eration rates after embolization [27, 28], other studies have demonstrated increased 
efficacy of radiosurgery with better obliteration rates after embolization [29].  
Figure 3. 
(A–C) An unruptured frontopolar AVM supplied by the orbitofrontal and frontopolar branches of the right ACA 
and drained by a single frontal cortical vein into the superior sagittal sinus. (D) The ETOH cast after embolization 
of two feeders in the same session with a curative intent. ETOH cast completely matches with the angioarchitecture 
of the AVM. Final angiograms (E and F) show complete obliteration of the AVM without any residual filling.
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In our practice, we recommend embolization before radiosurgery for cases with 
a volume larger than 10 cc, fistulous arteriovenous shunting, and intranidal 
aneurysms.
2.3 Curative embolization
Complete obliteration rates with embolization have been reported between 9.7 
and 14% with NBCA (N-butyl cyanoacrylate) [30]. During the Onyx era, complete 
obliteration rates with stand-alone embolization rose up to 18–51% [31]. Even 
higher cure rates up to 94% has been reported in smaller series with selective cases 
[32]. There were higher rates in AVMs with smaller size and a smaller number of 
arterial feeders (Figure 3). AVMs that have less prominent angiogenic nidus and 
predominantly fistulous AVMs compared to pure plexiform lesions were also more 
prone to complete obliteration. Small AVMs with single or less than two feeders 
with deep and central location are good candidates for stand-alone endovascular 
treatment. Larger size of the feeding artery also increases the chance of complete 
angiographic obliteration [33]. According to Valavanis and Yasargil, sulcal AVMs 
fed by pial arteries are more amenable to safe and effective embolization [34]. 
Most recent meta-analysis by Wu et al. [31] found an overall complication rate of 
Figure 4. 
(A) Ruptured cerebellar AVM supplied by the left anterior inferior cerebellar artery (AICA) branches and 
with drainage into the left transverse sinus. (B) A flow-related aneurysm on the left AICA and multiple 
intranidal aneurysms. Unsubtracted angiogram (C) after targeted embolization of the left AICA shows 
NBCA cast within the aneurysm that was most likely the culprit for the previous rupture and hemorrhage. 
Postembolization angiogram before surgery (D) shows occlusion of multiple aneurysms with residual AVM.
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24.1% including hemorrhage occurring in 9.7% of patients and procedure-related 
mortality rate of 1.5%. These rates are slightly higher compared with studies where 
the goal was adjunctive embolization before surgery or stereotactic radiotherapy. 
Even though stand-alone embolization with intent to cure has the potential to be 
a safe and efficient treatment, it must be preserved for select AVM cases or can be 
welcomed as an unanticipated result of an adjunctive endovascular treatment.
2.4 Targeted embolization
Intranidal aneurysm that may cause recurrent bleeding is the main target for 
embolization if a complete or near complete obliteration is not feasible (Figure 4). 
Aneurysms are more frequently seen in AVMs located in the frontal and occipital 
lobes. Deep arterial feeders not accessible by surgery are also a good target for 
embolization. Obliteration of the fistulous component of an AVM and decreasing 
AVM size by embolization may improve the cure rates after radiosurgery.
2.5 Palliative embolization
Although there is significant debate on the management of unruptured arterio-
venous malformations, intractable seizures or intractable headaches may dictate 
further treatment rather than medical management. Embolization can decrease the 
severity of these symptoms by theoretically reducing the steal phenomenon and 
venous hypertension [35, 36]. Embolization of the meningeal supply can relieve 
intractable headaches. Resolution of trigeminal neuralgia after embolization has 
been reported [37]. One must always consider risk-benefit balance when considering 
embolization for symptom relief because partial treatment of large AVMs by emboli-
zation or surgery may increase the risk of intracranial hemorrhage [27]. On the other 
hand, Meisel et al. [38] found that partially embolized AVMs have a lower risk of 
hemorrhage than the risk expected during the natural course of an untreated AVM.
3. Endovascular technique
3.1 Embolization procedure
Operator needs to know the goal of the endovascular treatment whether it is 
aiming a complete obliteration, presurgical grade reduction, size reduction before 
radiosurgery, or a targeted treatment to obliterate weak angioarchitectural points 
like flow-related aneurysms or intranidal aneurysm causing recurrent hemorrhage. 
Accordingly, with the specific aims, a game plan can be organized.
In most of the institutions, AVM embolization is performed under general 
anesthesia. Although some centers advocate conscious sedation over general 
anesthesia, we do not find it practical to perform embolization in awake patients 
considering potentially lengthy procedures and absolute need for immobilization 
during embolysate injection. Triaxial systems with intermediate distal access cath-
eters provide the advantage of much needed stability and momentum in distal and 
tortuous arterial feeders. A distal access catheter can be navigated to the level of the 
supraclinoid internal carotid artery, basilar artery, and even in the middle cerebral 
artery M1 or posterior cerebral artery P1 segments to have a better support.
If the aim is cure or significant size reduction, the ideal position of the micro-
catheter will be as distal as possible and close to the nidus of the AVM. One must 
be very careful during microcatheter navigation within the arterial feeders that are 
prone to dissection or perforation. The safest navigation technique is pushing the 
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leading microcatheter with a microwire inside and without microwire coming off. 
Microwire can lead the microcatheter if there is a kink or tortuosity preventing the 
microcatheter to move forward alone. As soon as the kink or tortuosity is over-
come, microwire is withdrawn inside. Navigation technique is different for flow- 
dependent microcatheters like Magic microcatheter (Balt, Montmorency, France). 
These microcatheters can be pushed with injection of saline and contrast mixtures 
and gentle pushing. One must pay attention to avoid kinking of these microcath-
eters because of poor visibility of the microcatheter shaft that tends to fold on itself 
when there is too much forward momentum. Gentle superselective microcatheter 
injections demonstrate the component supplied by the pedicle, venous drainage, 
and speed of shunting. If there is normal parenchymal blush from the same pedicle, 
another pedicle is chosen to prevent nontargeted embolization. En passage feeders 
are challenging because it can be difficult to choose them selectively, and distance 
to the normal main branch is usually very short for a safe injection. Microcatheter is 
flushed with saline after contrast injection and before introducing the D5 for NBCA 
or DMSO for ETOH. The working angle with the longest and straightest view of the 
microcatheter avoiding overlapping of the nidus and microcatheter must be chosen 
for the superselective angiogram and liquid embolic injection.
Ideal liquid embolic injection aims to penetrate into the nidus, completely 
obliterate the nidus, and reach to the very proximal portion of the venous outflow 
(Figure 5). This can be challenging in AVMs with multiple feeders and single drain-
ing vein. If the venous outflow is occluded with remaining arterial feeders and a 
Figure 5. 
(A–C) A previously ruptured cerebellar AVM in a 57-year-old-male with prior history of surgery for 
hematoma evacuation and partial resection of the AVM. (D and E) Complete obliteration of the AVM after 
embolization.
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large residual nidal component, a normal pressure breakthrough may occur leading 
to intracranial hemorrhage. Early venous stagnation with a residual persistent AVM 
can be an ominous sign and may require complete endovascular obliteration of the 
AVM if possible or immediate surgical resection (Figure 6).
Depending on the angioarchitectural characteristics and preferences and experi-
ence of the operator, EVOH or NBCA can be chosen. Although ETOH is used more 
frequently with the advantages of longer injection times or possibility of halting 
injections with intermittent angiographic control, NBCA is still preferred by some 
institutions [39]. Loh and Duckwiler [40] did not find significant differences between 
two agents in their capacity for at least 50% volume reduction, complication rates, 
and intraoperative blood loss. NBCA works through polymerization and requires 
meticulous preparation in order to prevent contamination with blood or saline that 
may cause premature polymerization. NBCA is prepared in a separate table or in an 
isolated part of the main table [40]. Operators change their gloves before preparation 
to prevent contamination and contact of blood with embolic agents. Microcatheter is 
flushed with D5 before NBCA injection. NBCA mixture can be tailored depending on 
the arteriovenous shunting. Most common mixture ratios of NBCA to Ethiodol are 1:3 
or 1:2 (NBCA:Ethiodol). Denser mixtures can be used if there is a fistulous compo-
nent with fast flow into the veins. More diluted mixtures can penetrate better into the 
nidus with the drawback of higher chance of reflux. Another technique to improve the 
NBCA penetration into the lesion is flushing the guiding catheter continuously with 
D5 dextrose solution while injecting the glue [41]. Penetration of the NCBA can be 
Figure 6. 
(A and B) An unruptured posterior fossa AVM. Final angiogram (C and D) after balloon microcatheter-
assisted embolization shows the onyx cast almost entirely matching with the AVM. (E and F) A tiny residual 
filling (arrow) without obvious early venous filling. Patient had surgery following embolization for complete 
resection of the AVM.
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stopped by stopping the D5 perfusion. NBCA is an adhesive agent and microcatheter 
must be removed briskly as soon as the reflux begins. In both NBCA and ETOH injec-
tions, microcatheter is removed while applying negative pressure by gentle aspiration.
ETOH (Onyx, Medtronic, Irvine, CA, USA or Squid, Emboflu, Gland, 
Switzerland) is a nonadhesive liquid embolic agent, which does not polymerize but 
precipitates when dissolved with dimethyl sulfoxide (DMSO). ETOH laminates 
along the venous wall without immediate occlusion of the vessel. Most frequently 
used ETOH-based liquid embolic agent is Onyx (Medtronic, Irvine, CA, USA). 
Dead space of the microcatheter is filled with the exact amount of DMSO before 
ETOH injection. Before injection, we usually mark the screen with a pen showing 
the landmarks including the most proximal tolerable reflux point on the microcath-
eter, boundaries of the AVM, and beginning of the venous drainage. Under blank 
roadmap, ETOH is injected slowly and reflux is watched. In the most popular “plug 
and push technique,” reflux forms a plug of ETOH at the tip of the microcatheter. 
Some institutions prefer the denser version of ETOH like Onyx 34 (Medtronic, 
Irvine, CA, USA) to form a plug. After the precipitation of ETOH forming a plug, 
antegrade penetration into the nidus with new injections is expected. Whenever 
there is further reflux, penetration into another arterial branch, or early venous 
penetration, injection is stopped for approximately 90 s. Halting injection for more 
than 2 min may cause clogging of the microcatheter. If there is no ETOH coming 
off the microcatheter tip or appearing under blank roadmap 60–90 s after starting 
injection, injection must be stopped and microcatheter is removed. Clogging of the 
microcatheter can result in rupture of the microcatheter shaft and extravasation 
of ETOH [42]. Intermittent angiograms can be done to control the obliteration of 
the AVM and the status of venous drainage while halting ETOH injections. After 
a satisfying obliteration is achieved, microcatheter is removed from the system. In 
ETOH cases, microcatheter is removed by applying constant gentle tension on the 
microcatheter. If there is a stubborn microcatheter stuck in the ETOH cast, patience 
with repetitive pulling with constant tension will remove the microcatheter in most 
of the cases.
Advances in microcatheter technology, development of detachable tip micro-
catheters, ETOH compatible dual lumen microballoon catheters, and evolution of 
liquid embolic agents have changed the paradigms in the endovascular treatment.
3.2 New trends in embolization techniques
3.2.1 Balloon-assisted embolization
DMSO compatible balloon microcatheters with double lumen (Scepter, 
Microvention Terumo, Aliso Viejo, CA, USA and Eclipse, Balt, Montmorency, 
France) allow injection of ETOH or NBCA while balloon is inflated within the 
feeding artery [43, 44]. This creates a wedge positioning of the microcatheter like 
situation or forms a transient plug to increase the penetration of liquid embolic 
with minimal or no reflux. This will theoretically decrease the fluoroscopy time and 
radiation dose and increase the ease of microcatheter removal after injection. This 
technique is especially effective in fistulous AVMs with large caliber feeders. Balloon 
inflation prevents reflux and allows a more controlled injection in flow arrest condi-
tions. Special attention must be paid during inflation in order to prevent rupture of 
the feeder. If there is a problem with balloon inflation, uninflated balloon should be 
replaced as it may increase the chance of catheter entrapment [45]. If there is reflux 
along the inflated balloon, further gentle inflation usually prevents reflux. Extreme 
caution must be paid during inflation of the balloon within the arterial feeders to 
prevent overinflation and rupture.
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3.2.2 Transvenous embolization
Although this technique recalls the venous outflow occlusion, one of the most 
fearful situations for a neuroendovascular specialist during AVM embolization, 
there is increasing use of transvenous embolization in selective cases [45–47]. 
Deeply located hemorrhagic AVMs with small tortuous feeders or en passage feed-
ers may have complex anatomy precluding the use of transarterial embolization. 
Transvenous embolization have theoretical advantages of better penetration of 
the AVM nidus, less risk of ischemic events due to arterial occlusion, and relatively 
easier navigation through enlarged and usually straighter veins. Significantly high 
complete obliteration rates between 80 and 100% [47, 48] were reported in the 
literature. A transjugular venous access with a triaxial system including a sturdy 
guiding system of an 8F sheath and distal access catheter is crucial for safe and 
efficient practice of transvenous embolization. Alternatively, a 6F transjugular 
access with a 6F distal access catheter can be used. Detachable tip microcatheters 
or balloon microcatheters in feasible anatomy may prevent reflux and occlusion 
of the venous drainage. Some centers intentionally let an approximately 3 cm 
reflux after a longer injection and leave the microcatheter inside the system after 
cutting the microcatheter shaft at the skin incision site. Mendes et al. [47] did not 
report any thromboembolism associated with transvenous embolization cases 
with transjugular access where all microcatheters were left intentionally within 
the venous system. Arterial access and arterial flow arrest with transient balloon 
occlusion or simultaneous transarterial embolization should be used if techni-
cally feasible. Although there is no established standard practice of transvenous 
embolization, theoretical criteria to select cases include small lesions with a nidus 
of <2 cm, hemorrhagic AVMs, patients who are not good surgical candidates, 
arterial feeders that are not amenable to transarterial embolization like en passage 
feeders, lenticulostriate arteries or choroidal arteries, and AVMs preferably with a 
single drainage vein [46, 48]. Nonadhesive ETOH should be used for transvenous 
embolization [49]. Systemic hypotension during and after transvenous emboliza-
tion is also crucial for decreasing the arterial pressure that must be overcome for 
better nidal penetration. Another technical challenge for transvenous emboliza-
tion arises from frequently encountered venous anatomical variations and fragile 
structure of the cerebral veins that may lead to disastrous consequences in case of 
vessel injury. One must pay extreme caution for safe transvenous navigation of the 
microcatheter without leading microwire. Aneurysms, ectasia, or stenosis in the 
draining vein may preclude transvenous embolization due to high risk of vessel 
injury during navigation.
3.2.3 Pressure cooker technique
Pressure cooker technique (PCT), first described by Chapot et al. [50], applies 
a plug composed of coils and glue instead of the usual ETOH plug used in the 
regular plug and push technique. Coils are deployed and NBCA is injected to form 
a plug. A microcatheter for ETOH injection is placed in the optimal position in the 
feeding artery followed by a second microcatheter placed in between the tip of the 
first microcatheter and detachment zone. As described by the sheeping technique, 
placement of the first microcatheter usually facilitates the navigation of the second 
security microcatheter [32, 51]. A 1.2F Magic (Balt, Montmorency, France) micro-
catheter is used in small caliber vessels and Echelon 10 (Medtronic, Irvine, CA, 
USA) is used as a second microcatheter in relatively larger caliber arterial feeders. 
Since detachable coils are not compatible with Magic 1.2F microcatheter, injectable 
flow coils (SPIF, Balt, Montmorency, France) are used. In case of larger caliber 
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vessels with high flow arteriovenous shunts, injectable coils may flow unintention-
ally toward the tip of the first microcatheter. Detachable coils are deployed through 
a regular 1.7F like Echelon 10 (Medtronic, Irvine, CA, USA) for precise placement 
of the coil and glue plug. This type of plug is more resistant to ETOH reflux and 
facilitates a more forceful and continuous ETOH injection. It creates a wedge-like 
position similar to ETOH injection through the balloon microcatheters. The theo-
retical advantages compared to balloon-assisted embolization are better navigability 
of flow-directed microcatheters and avoidance of risk of vessel perforation during 
balloon inflation.
4. Complications of the endovascular treatment
Overall morbidity and mortality rates from the largest series of AVM embo-
lization range from 0 to 22% and 0 to 3%, respectively [52–56]. Intracranial 
hemorrhage during or after the embolization can be seen in between 2 and 4.7%. 
Most common reason for hemorrhage is vessel perforation due to microcatheter 
or microwire manipulations. Venous outflow obstruction and normal perfu-
sion pressure breakthrough are other mechanisms that may cause bleeding after 
embolization. Normal perfusion pressure breakthrough is believed to occur due 
to overdilated capillaries in the parenchyma surrounding the AVM in the setting 
of steal phenomenon or ischemia. After embolization or resection of the AVM, 
increased pressure or perfusion in the surrounding parenchyma may cause rupture 
of the maximally dilated capillaries [57]. Staged embolization is preferred in large 
AVMs in order to prevent normal perfusion breakthrough phenomenon [58]. If the 
surgical resection is not planned to immediately follow the embolization, a staged 
embolization in several sessions is performed. Although there is no established rule, 
less than 50% size reduction is aimed in every session in order to prevent postembo-
lization hemorrhage. About 4–6 weeks can be waited in between every session for 
hemodynamic stabilization. If there is significant slowing of the venous drainage 
during any moment of embolization, either complete obliteration must be achieved 
by embolization or surgical resection must be performed urgently following 
embolization. Therefore, it is utmost important to evaluate the venous drainage pat-
tern before and immediately after the embolization. In rare cases, perforation and 
bleeding may occur during superselective microcatheter injection in a small branch. 
If there is any concern for intraoperative rupture or postprocedural neurological 
deterioration happens, a brain computerized tomography must be obtained to rule 
out hemorrhage. In case of hematoma with mass effect or impending expansion 
risk, emergent craniotomy for hematoma evacuation helps minimize neurological 
deficit and may avoid mortal consequences [59].
Ischemic complications can occur due to thromboembolism from the embolic 
material or thrombus formation within or along the guiding catheter or microcath-
eter. Mechanisms or thromboembolism are reflux or nontargeted flow of the liquid 
embolic into a normal branch during embolization. Heparinization is routinely used 
during AVM embolizations. Other general complications related to angiographic 
procedure include groin hematoma, retroperitoneal hematoma, arteriovenous 
fistula, and contrast nephropathy with similar frequencies compared to other 
neurointerventional procedures.
Buffalo grading system [60] is used to stratify the risks associated with endovas-
cular treatment with curative intent. Risk of the endovascular treatment increases 
with number of arterial feeders, smaller diameter of the feeders, and eloquent loca-
tion. One point is given for AVMs with one or two arterial feeders, 2 points is given 
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for three or four arterial feeders, and 3 points is assigned for four or more pedicles. 
If the diameter of the most feeders is less than 1 mm or AVM is in an eloquent loca-
tion, an additional point is given. Starke et al. [61] proposed another scale to predict 
various factors increasing complication risk in AVM embolizations. This scale is 
very similar to Spetzler-Martin grading system for surgical morbidity-mortality 
and includes same factors including size (1 point for <3 cm and 2 points for >6 cm), 
eloquent location, and deep venous drainage. They proposed the need for more than 
one session of embolization as an additional risk factor with increased complica-
tion rate. However, Crowley et al. [56] did not find any significant difference in 
the complication and morbidity/mortality rates depending on the Spetzler-Martin 
grades. The same study did neither show a significant difference in complication 
rates between the ETOH versus NBCA cases.
Microcatheter retention may occur between 3 and 8% of cases [42]. Risk of 
microcatheter retention increases after longer injections with long reflux, in 
smaller branches and branches with significant curves and tortuosity. If the vessel 
accommodating the microcatheter has tortuosity, long refluxes must be avoided. 
Safe reflux for an efficient push and plug technique is usually between 15 and 
20 mm. Smaller vessels with or without tortuosity require a smaller reflux of less 
than 10 mm [50]. Although ETOH is nonadhesive and initially microcatheter 
retention was expected to decrease with ETOH use, clinical practice and experi-
ence demonstrated the contrary. The risk increased due to longer injection times 
and the need for a significant reflux to form a plug for efficient ETOH injection. 
Loh and Duckwiler [40] found higher incidence of microcatheter retention and 
difficulty in removing the delivery microcatheter in the first trial comparing 
Onyx to NBCA, which led to FDA approval of the Onyx. ETOH is less throm-
bogenic than NBCA and does not cause immediate occlusion in case of an unin-
tended flux.
Development of detachable tip microcatheters including Apollo (Medtronic, 
Irvine, CA, USA) and Sonic (Balt, Montmorency, France) has substantially 
decreased the incidences of microcatheter retention [62]. These microcatheters 
have variable lengths (1.5 or 3 cm) of detachable tip segment that allows better 
estimate of tolerable reflux thanks to markers, and detachment will occur if there is 
enough reflux to create a tension point. Sonic (Balt, Montmorency, France) micro-
catheter usually detaches after a long injection with substantial reflux; whereas 
Apollo (Ev3) microcatheter may not detach in many cases and can be retrieved as a 
whole without detachment.
Introduction of distal access catheters helped better navigation of very distal 
tortuous feeders and facilitated retrieval of microcatheters after a long injection. 
The use of distal access catheters is almost the standard of practice especially for 
cases with superficial lesions with distal and tortuous feeders. Distal location of 
a guide catheter eliminates the need for repeated navigation of a microcatheter 
through a tortuous supraclinoid internal carotid, anterior, middle cerebral artery, or 
basilar artery.
Although recanalization after complete obliteration of an AVM is extremely 
rare, there is still risk of recanalization that mandates angiographic follow-up 
after complete obliteration. Potts et al. [63] in their extensive review of multiple 
series of AVMs cured with embolization found 4.5% recurrence rate on follow-up 
angiography. However, there was not any case of recurrence with rupture or any 
adverse event during follow-up period. Mechanisms that may lead to recurrence 
include incomplete embolization due to nonvisualization of a component during 
initial embolization, mass effect from a hematoma, or recanalization of an initially 
thrombosed compartment.
Vascular Malformations of the Central Nervous System
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